Immunosuppression: Today, Tomorrow, and Withdrawal

ABSTRACT

The advent of modern immunosuppressive agents is arguably the single most important factor that has allowed liver transplantation to advance in the past several decades from a dubious and dangerous venture to the treatment of choice for end-stage liver disease. During the past two decades, a large array of immunosuppressants have greatly expanded the armamentarium used by transplant physicians and surgeons to prevent and treat liver allograft rejection. The availability of these drugs has resulted in the excellent short-term and long-term outcomes achieved in liver transplantation. However, these drugs continue to lack specificity and are associated with acute and chronic toxicities. Although the liver is considered a relatively tolerogenic organ, we have yet to attain the “Holy Grail” of transplantation, that is, transplantation tolerance, in a consistent manner. Thus, the liver transplant recipient is still being sentenced to a lifelong course of chronic immunosuppression. Small molecules, biologic agents such as antibodies and fusion proteins, and corticosteroids continue to play a central role in immunosuppressive regimens used in liver transplantation. In addition several novel immunosuppressive agents have been used in preclinical and clinical trials that show promise for use in the near future. We review current immunosuppressive medications and describe the new developments that are on the horizon.

KEYWORDS

Immunosuppression - liver transplant

REFERENCES

• 1 Wiesner R H, Demetris A J, Belle S H et al.. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome.  Hepatology. 1998;  28 638-645
• 2 Ojo A O, Held P J, Port F K et al.. Chronic renal failure after transplantation of a nonrenal organ.  N Engl J Med. 2003;  349 931-940
• 3 Vezina C, Kudelski A, Sehgal S N. Rapamycin (AY-22,989), a new antifungal antibiotic. I: taxonomy of the producing streptomycete and isolation of the active principle.  J Antibiot (Tokyo). 1975;  28 721-726
• 4 Murgia M G, Jordan S, Kahan B D. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients.  Kidney Int. 1996;  49 209-216
• 5 Trotter J F, Wachs M E, Trouillot T E et al.. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus.  Liver Transpl. 2001;  7 401-408
• 6 Legendre C, Campistol J M, Squifflet J P et al.. Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation.  Transplant Proc. 2003;  35 151S-153S
• 7 Chueh S C, Kahan B D. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis.  Transplantation. 2003;  76 375-382
• 8 Eason J D, Blazek J, Mason A et al.. Steroid-free immunosuppression through thymoglobulin induction in liver transplantation.  Transplant Proc. 2001;  33 1470-1471
• 9 Eason J D, Nair S, Cohen A J et al.. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy.  Transplantation. 2003;  75 1396-1399
• 10 Calmus Y, Scheele J R, Gonzalez-Pinto I et al.. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.  Liver Transpl. 2002;  8 123-131
• 11 Neuhaus P, Clavien P A, Kittur D et al.. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.  Liver Transpl. 2002;  8 132-142
• 12 Emre S, Gondolesi G, Polat K et al.. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.  Liver Transpl. 2001;  7 220-225
• 13 Vincenti F, Ramos E, Brattstrom C et al.. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.  Transplantation. 2001;  71 1282-1287
• 14 Hirose R, Roberts J P, Quan D et al.. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.  Transplantation. 2000;  69 307-311
• 15 Halloran P F. Immunosuppressive drugs for kidney transplantation.  N Engl J Med. 2004;  351 2715-2729
• 16 Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation.  Am J Transplant. 2002;  2 898-903
• 17 Brinkmann V, Cyster J G, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.  Am J Transplant. 2004;  4 1019-1025
• 18 Podder H, Kahan B D. Janus kinase 3: a novel target for selective transplant immunosuppression.  Expert Opin Ther Targets. 2004;  8 613-629
• 19 Changelian P S, Flanagan M E, Ball D J et al.. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.  Science. 2003;  302 875-878
• 20 Borie D C, Changelian P S, Larson M J et al.. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.  Transplantation. 2005;  79 791-801
• 21 Birsan T, Dambrin C, Klupp J et al.. Effects of the malononitrilamide FK778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers.  Transpl Immunol. 2003;  11 163-167
• 22 Bilolo K K, Ouyang J, Wang X et al.. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat.  Transplantation. 2003;  75 1881-1887
• 23 Yamamoto S, Okuda T, Yamasaki K et al.. FK778 controls acute rejection after rat liver allotransplantation showing positive interaction with FK506.  Transplant Proc. 2005;  37 126-129
• 24 Joshi A, Bauer R, Kuebler P et al.. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.  J Clin Pharmacol. 2006;  46 10-20
• 25 Nicolls M R, Gill R G. LFA-1 (CD11a) as a therapeutic target.  Am J Transplant. 2006;  6 27-36
• 26 Corbascio M, Ekstrand H, Osterholm C et al.. CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely.  Transpl Immunol. 2002;  10 55-61
• 27 Zheng X X, Sanchez-Fueyo A, Sho M et al.. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance.  Immunity. 2003;  19 503-514
• 28 Knechtle S J, Pirsch J D, Fechner J J et al.. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.  Am J Transplant. 2003;  3 722-730
• 29 Kirk A D, Hale D A, Mannon R B et al.. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).  Transplantation. 2003;  76 120-129
• 30 Pescovitz M D. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation.  Pediatr Transplant. 2004;  8 9-21
• 31 Larsen C P, Pearson T C, Adams A B et al.. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.  Am J Transplant. 2005;  5 443-453
• 32 Bretscher P, Cohn M. A theory of self-nonself discrimination.  Science. 1970;  169 1042-1049
• 33 Linsley P S, Ledbetter J A. The role of the CD28 receptor during T cell responses to antigen.  Annu Rev Immunol. 1993;  11 191-212
• 34 Sayegh M H, Turka L A. The role of T-cell costimulatory activation pathways in transplant rejection.  N Engl J Med. 1998;  338 1813-1821
• 35 Turka L A, Linsley P S, Lin H et al.. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.  Proc Natl Acad Sci USA. 1992;  89 11102-11105
• 36 Larsen C P, Elwood E T, Alexander D Z et al.. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.  Nature. 1996;  381 434-438
• 37 Kirk A D, Harlan D M, Armstrong N N et al.. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.  Proc Natl Acad Sci USA. 1997;  94 8789-8794
• 38 Vincenti F, Larsen C, Durrbach A et al.. Costimulation blockade with belatacept in renal transplantation.  N Engl J Med. 2005;  353 770-781
• 39 Adams A B, Shirasugi N, Jones T R et al.. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival.  J Immunol. 2005;  174 542-550